Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Alzheimer disease

Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?

Nature Reviews Neurology volume 19, pages 71–72 (2023)Cite this article

Subjects

Findings from a worldwide cohort of cognitively unimpaired individuals demonstrate that the presence of two canonical Alzheimer disease biomarkers — amyloid and tau — can reliably predict progression to mild cognitive impairment in the short-term. The results support the use of these biomarkers to diagnose preclinical Alzheimer disease in a clinical setting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).

    Article  Google Scholar 

  2. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. https://doi.org/10.1002/alz.12068 (2020).

  3. Jack, C. R. Jr. et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013).

    Article  CAS  Google Scholar 

  4. Jack, C. R. Jr. et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).

    Article  CAS  Google Scholar 

  5. Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 79, 975–985 (2022).

    Article  Google Scholar 

  6. Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381–2387 (2022).

    Article  CAS  Google Scholar 

  7. van der Kall, L. M. et al. Association of β-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Neurology 96, e662–e670 (2021).

    Google Scholar 

  8. Wilkins, C. H. et al. Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the imaging dementia-evidence for amyloid scanning (IDEAS) cohort study. JAMA Neurol. 79, 1139–1147 (2022).

    Article  Google Scholar 

  9. Decourt, B. et al. The cause of Alzheimer’s disease: the theory of multipathology convergence to chronic neuronal stress. Aging Dis. 13, 37–60 (2022).

    Article  Google Scholar 

  10. Decourt, B., Noorda, K., Noorda, K., Shi, J. & Sabbagh, M. N. Review of advanced drug trials focusing on the reduction of brain beta-amyloid to prevent and treat dementia. J. Exp. Pharmacol. 14, 331–352 (2022).

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by National Institutes of Health grants R01AG059008 and R01AG073212, ADDF GC2013717 and the Barrow Neurological Foundation. We thank the staff of Neuroscience Publications at Barrow Neurological Institute for assistance with copy editing, manuscript preparation and submission.

Author information

Authors and Affiliations

  1. Alzheimer’s Clinical and Translational Research Lab, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, USA

    Marwan N. Sabbagh

  2. Translational Neurodegenerative Research Lab, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

    Boris DeCourt

Authors
  1. Marwan N. Sabbagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Boris DeCourt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marwan N. Sabbagh.

Ethics declarations

Competing interests

B.D. has consulted for Seq Biomarque and TransDermix. M.N.S. has ownership interests (stock or stock options) in Alzheon, Athira Pharma, Cortexyme/Quince Therapeutics, Lighthouse Pharmaceuticals, NeuroReserve, NeuroTau, Seq BioMarque, TransDermix, and uMethod Health; has consulted for Corium, Eisai, Lilly, NeuroTherapia, Novo Nordisk, Prothena, Roche-Genentech, Signant Health, Synaptogenix, and T3D; has received royalties from Humanix; and is on the board of directors of EIP Pharma.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sabbagh, M.N., DeCourt, B. Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic?. Nat Rev Neurol 19, 71–72 (2023). https://doi.org/10.1038/s41582-022-00767-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-022-00767-x

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing